Trokendi XR, 25mg recall — Supernus Pharmaceuticals, Inc. (Unclassified)
Supernus Pharmaceuticals, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Trokendi XR, 25mg — an Unclassified recall, initiated 2026-07-06 and posted to the FDA enforcement report on 2026-07-29, for which the source publishes no recall number. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Dissolution Specifications”. From the product description, the form is extended-release capsules, the strength given is 25mg, the package is described as 30 Capsules and it is marked Rx only. 1 National Drug Code number is printed in the record: 17772-101-30. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in MD, United States. It is the only recall number the FDA has filed under event ID 99375. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | N/A — the source publishes no recall number for this record |
|---|---|
| FDA event ID | 99375 |
| Classification | Unclassified |
| Status | Ongoing |
| Recalling firm | Supernus Pharmaceuticals, Inc. |
| Recall initiated | 2026-07-06 |
| Reported by FDA | 2026-07-29 |
| Report lag | 23 days from initiation to report |
| Distribution | US Nationwide. — Nationwide (US) |
| Firm location on record | MD, United States |
| Product description (source) | Trokendi XR, topiramate extended-release capsules, 25mg, 30 Capsules, Rx only, Manufactured by: Catalent Pharma Solutions, Winchester, KY 40391 USA, Manufactured for: Supernus Pharmaceuticals, Inc., Rockville, MD 20850 USA, NDC 17772-101-30. |
Reason reported by FDA
Failed Dissolution Specifications
3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
7 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.
| Product named | Trokendi XR |
|---|---|
| Form | Extended-Release Capsules |
| Strength | 25mg |
| Package | 30 Capsules |
| NDC | 17772-101-30 |
| Marketing category | Rx only |
| Manufactured by | Catalent Pharma Solutions, Winchester |
| Manufactured for | Supernus Pharmaceuticals, Inc. |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 16 are the Unclassified ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Levothyroxine Sodium Tablets, 25 mcg | D-0700-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0701-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0702-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 88 mcg | D-0703-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 112 mcg | D-0704-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 125 mcg | D-0705-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 150 mcg | D-0706-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 25 mcg | D-0707-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0708-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0709-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 125 mcg | D-0710-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Levothyroxine Sodium Tablets, 150 mcg | D-0711-2026 | Major Pharmaceuticals | Class II | 2026-07-29 |
| Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg | D-0712-2026 | Ascend Laboratories, LLC | Class II | 2026-07-29 |
| Lidolog Kit, 2% | D-0713-2026 | Asclemed Usa Inc. | Class III | 2026-07-29 |
| Rohto Cooling Eye Drops ALL-IN-ONE, 0.2% | D-0715-2026 | Rohto-mentholatum (vietnam) Co., Ltd. | Class II | 2026-07-29 |
| Rohto Cooling Eye Drops Max Strength, 0.03% | D-0716-2026 | Rohto-mentholatum (vietnam) Co., Ltd. | Class II | 2026-07-29 |
Reading this record
Unclassified is the FDA's own severity tier for the recall action — 1 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 17772-101-30 at the FDA source to confirm it is covered.
Namespace context: the Unclassified index (1 records) and the recall hub (250 records, 118 FDA events); Supernus Pharmaceuticals, Inc. (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for this recall as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22N%2FA%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-29
- Ingested
- 2026-08-22
- Record hash
3f7734662a6f0e43
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.